Abstract
Although enzyme replacement therapy has had a considerable impact on the management of patients with Fabry disease, it is essential that attention is also given to supportive therapy. In this chapter a general overview about ancillary therapy is given. The great variability of clinical symptoms faced by patients with Fabry disease need the involvement from many different specialists, as well as a wide range of concomitant treatments. Coordinating a good multidisciplinary approach for each patient and ensuring that treatment is made as convenient as possible may offer a more positive impact on the quality of life of those patients affected by Fabry disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
MacDermot J, MacDermot KD (2001) Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol 429:121–125
Germain DP (2002) Fabry’s disease (alpha-galactosidase-A deficiency): recent therapeutic innovations. J Soc Biol 196:183–190
Ries M, Mengel E, Kutschke G et al (2003) Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J Inherit Metab Dis 26:413–414
Lockman LA, Hunninghake DB, Krivit W, Desnick RJ (1973) Relief of pain of Fabry’s disease by diphenylhydantoin. Neurology 23:871–875
Lenoir G, Rivron M, Gubler MC et al (1977) Fabry’s disease. Carbamazepine therapy in acrodyniform syndrome. Arch Fr Pediatr 34:704–716
Saarto T, Wiffen PJ (2005) Antidepressants for neuropathic pain. Cochrane Database Syst Rev 3:CD005454
Tahir H, Jackson LL, Warnock DG (2007) Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with Agalsidase-beta. J Am Soc Nephrol 18:2609–2617
Wanner C, Breunig F (2007) Fabry nephropathy and the case for adjunctive renal therapy. J Am Soc Nephrol 18:2426–2428
Bechara FG, Huesmann M, Altmeyer P, Hoffmann K, Jansen T (2002) Angiokeratoma of the glans penis: successful treatment with Nd: YAG laser. Acta Paediatr Suppl 439:143
Mohrenschlager M, Brau-Falco M, Ring J, Abeck D (2003) Fabry disease: recognition and management of cutaneous manifestations. Am J Clin Dermatol 4:189–196
Brown LK, Miller A, Bhuptani A et al (1997) Pulmonary involvement in Fabry disease. Am J Respir Crit Care Med 155:1004–1010
DeGraba TT, Azhar S, Dignat George F et al (2000) Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 47:229–233
Cantor WJ, Daly P, Iwannochko M, Clarke JT, Cusimano RJ, Butany J (1998) Cardiac transplantation for Fabry’s disease. Can J Cardiol 14:81–84
Magage S, Linhart A, Bultas J et al (2005) Fabry disease: percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outflow tract obstruction in a classically affected male. Echocardiography 22:333–339
Moore DF, Kaneski CR, Askari H, Schiffmann R (2007) The cerebral vasculopathy of Fabry disease. J Neurol Sci 257:258–263
Diener HC, Bogousslavsky J, Brass LM et al (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364:331–337
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Netherlands
About this chapter
Cite this chapter
Whybra-Trümpler, C. (2010). Symptomatic and Ancillary Therapy. In: Elstein, D., Altarescu, G., Beck, M. (eds) Fabry Disease. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9033-1_31
Download citation
DOI: https://doi.org/10.1007/978-90-481-9033-1_31
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-9032-4
Online ISBN: 978-90-481-9033-1
eBook Packages: MedicineMedicine (R0)